Patient Derived Xenograft/PDX Models Report 2025: Mice PDX Models Segment is Forecast to Reach US$799.3 Million by 2030 with a CAGR of a 14.8%, Rat PDX Models is set to Grow at 12.5% CAGR
31 janv. 2025 05h16 HE
|
Research and Markets
Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Patient Derived Xenograft / PDX Models - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for...
In Vivo CRO Market Projected to Reach USD 7.96 Billion by 2030 with Substantial Growth Across Regions and Segments
14 janv. 2025 10h49 HE
|
Research and Markets
Dublin, Jan. 14, 2025 (GLOBE NEWSWIRE) -- The "In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts,...
Preclinical CRO Industry Assessment: Growth Opportunities and Strategies to 2033
11 déc. 2024 07h26 HE
|
Research and Markets
Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "Preclinical CRO Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering.This report describes and...
Eradivir’s EV25 therapeutic proven to reduce advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
21 nov. 2024 09h24 HE
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that licenses innovations from Purdue Research Foundation, has developed a patent-pending antiviral...
Preclinical Imaging (In-VIVO) Strategic Research Report 2023-2030: Adoption of AI and Machine Learning in Image Analysis Drives Market Dynamics
30 août 2024 05h38 HE
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Preclinical Imaging (In-VIVO) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for...
Biotech company Eradivir is developing lead drug EV25 to treat influenza
09 juil. 2024 14h24 HE
|
Purdue Research Foundation
WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to...
GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials
07 juin 2024 03h32 HE
|
Research and Markets
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...
Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Report 2024: USA Dominating with 5 Therapies, FDA Orphan Designation, Proprietary Development Technologies by Companies
14 mai 2024 05h38 HE
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering....
Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase
29 avr. 2024 07h32 HE
|
Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Global CD70 Targeting Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. ...
Global In Vivo CRO Market Analysis Report 2024-2030, Featuring IQVIA, Crown Bioscience, Taconic Biosciences, PsychoGenics, Evotec, Janvier Labs, Biocytogen Boston, GemPharmatech and Parexel
15 avr. 2024 09h47 HE
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Global In Vivo CRO Market Size, Share & Trends Analysis Report by Model Type (Rodent Based, Non-rodent Based), Modality (Small Molecule, Large...